ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,321.41
0.25%
Dow Jones
39,872.99
0.17%
US Dollar vs MXN
16.6106
-0.07%
Brent Oil
82.295
-0.18%
Bitcoin
70,282.23
0.22%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) Noticias

ABUS Arbutus Biopharma Corporation

3.16
0.09 (2.93%)
21 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Arbutus Biopharma Corporation ABUS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.09 2.93% 3.16 18:10:56
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.10 3.06 3.215 3.21 3.07
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
17/5/202408:03EDGAR2Form SC 13D/A - General statement of acquisition of..
17/5/202408:00BWWhitefort Capital Publishes Open Letter to Arbutus Biopharma..
09/5/202407:00EDGAR2Form SC 13D - General statement of acquisition of beneficial..
07/5/202406:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
02/5/202406:30GLOBEArbutus Reports First Quarter 2024 Financial Results and..
02/5/202406:25GLOBEArbutus Announces Retirement of Chief Scientific Officer,..
18/4/202406:30GLOBEArbutus to Report First Quarter 2024 Financial Results and..
04/4/202407:30GLOBEArbutus Biopharma Announces Claim Construction Ruling in its..
08/3/202406:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
05/3/202415:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202406:31EDGAR2Form 8-K - Current report
29/2/202406:30GLOBEArbutus Reports Fourth Quarter and Year End 2023 Financial..
15/2/202406:30GLOBEArbutus to Report Fourth Quarter and Year End 2023 Financial..
14/2/202415:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202409:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202418:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202406:31EDGAR2Form 8-K - Current report
08/1/202406:30GLOBEArbutus Announces 2024 Corporate Objectives and Provides..
04/1/202415:09EDGAR2Form 8-K - Current report
21/11/202307:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/11/202315:02EDGAR2Form 8-K - Current report
08/11/202306:30GLOBEArbutus to Present at Jefferies London Healthcare Conference
07/11/202315:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:31EDGAR2Form 8-K - Current report
07/11/202306:30GLOBEArbutus Reports Third Quarter 2023 Financial Results and..
07/11/202306:16EDGAR2Form 8-K - Current report
07/11/202306:15GLOBEArbutus Announces CEO, William Collier, to Retire December..
24/10/202306:30GLOBEArbutus to Report Third Quarter 2023 Financial Results and..
18/10/202306:30GLOBEArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B..
11/10/202307:06EDGAR2Form 8-K - Current report
11/10/202307:05GLOBEArbutus Announces Multiple Abstracts Accepted for..
11/9/202316:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11/9/202315:16EDGAR2Form 8-K - Current report
11/9/202315:15GLOBEArbutus Announces Pipeline Updates and Dosing of the First..
07/9/202306:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
03/8/202315:18EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/8/202315:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202306:31EDGAR2Form 8-K - Current report
03/8/202306:30GLOBEArbutus Reports Second Quarter 2023 Financial Results..
20/7/202306:30GLOBEArbutus to Report Second Quarter 2023 Financial Results and..
13/7/202315:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202315:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202315:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202315:48EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202315:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202315:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202306:31EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
ABUS
Arbutus Biopharma
BOV
IBSD11
Indice Bovespa SD TR
USOTC
AREVF
AREV Life Sciences Global (PK)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados